Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer

被引：0
|
作者：
Sophie Broutin
Adam Stewart
Parames Thavasu
Angelo Paci
Jean-Michel Bidart
Udai Banerji
机构：
[1] Gustave Roussy,Département de Biologie et Pathologie Médicales
[2] Université Paris-Saclay,undefined
[3] Villejuif,undefined
[4] F-94805,undefined
[5] France,undefined
[6] The Institute of Cancer Research,undefined
[7] Clinical Pharmacology and Trials Team,undefined
来源：
British Journal of Cancer | 2016年 / 115卷
关键词：
drug combinations; NSCLC; KRAS mutant; MEK inhibitor; trametinib; m-TOR inhibitor; AZD2014;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：549 / 552
页数：3
相关论文
共 50 条
  • [21] Combined inhibition of MEK and p38 efficiently inhibits cell growth of KRAS-mutated non-small cell lung cancer
    Sunaga, Noriaki
    Miura, Yosuke
    Tsukagoshi, Yusuke
    Kasahara, Norimitsu
    Sakurai, Reiko
    Kaira, Kyoichi
    Hisada, Takeshi
    CANCER SCIENCE, 2018, 109 : 587 - 587
  • [22] Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer
    Shimamura, Takeshi
    Chen, Zhao
    Soucheray, Margaret
    Carretero, Julian
    Kikuchi, Eiki
    Tchaicha, Jeremy H.
    Gao, Yandi
    Cheng, Katherine A.
    Cohoon, Travis J.
    Qi, Jun
    Akbay, Esra
    Kimmelman, Alec C.
    Kung, Andrew L.
    Bradner, James E.
    Wong, Kwok-Kin
    CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6183 - 6192
  • [23] Combined EGFR and MEK inhibition prevents the emergence of drug resistance in EGFR mutant non-small cell lung cancer (NSCLC)
    Tricker, Erin M.
    Xu, Chunxiao
    Ercan, Dalia
    Ogino, Atsuko
    Wong, Kwok-kin
    Janne, Pasi
    CANCER RESEARCH, 2014, 74 (19)
  • [24] Activity-based protein profiling reveals adaptive response to pharmacological MEK inhibition in KRAS mutant non-small cell lung cancer
    Kim, Jae-Young
    Fang, Bin
    Welsh, Eric A.
    Kinose, Fumi
    Li, Jiannong
    Eschrich, Steven A.
    Koomen, John M.
    Haura, Eric B.
    MOLECULAR CANCER RESEARCH, 2014, 12
  • [25] Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer
    Luiz Henrique Araujo
    Bianca Mendes Souza
    Laura Rabelo Leite
    Sabrina A. F. Parma
    Natália P. Lopes
    Frederico S. V. Malta
    Maíra C. M. Freire
    BMC Cancer, 21
  • [26] Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer
    Araujo, Luiz Henrique
    Souza, Bianca Mendes
    Leite, Laura Rabelo
    Parma, Sabrina A. F.
    Lopes, Natalia P.
    Malta, Frederico S. V.
    Freire, Maira C. M.
    BMC CANCER, 2021, 21 (01)
  • [27] SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
    Sara Mainardi
    Antonio Mulero-Sánchez
    Anirudh Prahallad
    Giovanni Germano
    Astrid Bosma
    Paul Krimpenfort
    Cor Lieftink
    Jeffrey D. Steinberg
    Niels de Wit
    Samuel Gonçalves-Ribeiro
    Ernest Nadal
    Alberto Bardelli
    Alberto Villanueva
    Rene Bernards
    Nature Medicine, 2018, 24 : 961 - 967
  • [28] SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
    Mainardi, Sara
    Mulero-Sanchez, Antonio
    Prahallad, Anirudh
    Germano, Giovanni
    Bosma, Astrid
    Krimpenfort, Paul
    Lieftink, Cor
    Steinberg, Jeffrey D.
    de Wit, Niels
    Goncalves-Ribeiro, Samuel
    Nadal, Ernest
    Bardelli, Alberto
    Villanueva, Alberto
    Bernards, Rene
    NATURE MEDICINE, 2018, 24 (07) : 961 - +
  • [29] THE SIGNIFICANCE OF HISTOLOGY IN NON-SMALL-CELL LUNG-CANCER
    ROSENTHAL, SA
    CURRAN, WJ
    CANCER TREATMENT REVIEWS, 1990, 17 (04) : 409 - 425
  • [30] COMBINED SMALL-CELL AND NON-SMALL-CELL LUNG-CANCER
    MANGUM, MD
    GRECO, FA
    HAINSWORTH, JD
    HANDE, KR
    JOHNSON, DH
    JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (05) : 607 - 612
12345